Security key
482929106
Kalaris Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KLRS)
CUSIP: 482929106
Q1 2026 13F Holders as of 31 Mar 2026
- Security type / class
- Equity / Common Stock, $0.0001 par value per share
- Total 13F shares
- 18,578,668
- Total 13F value
- $107,183,840
- Share change
- +582,012
- SEC-reported price per share
- $5.77
- Number of holders
- 57
- Value change
- +$2,867,539
- Number of buys
- 27
- Number of sells
- 13
- Shares outstanding
- 23,801,814
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q1 2026
Institutions
57
Top holders
10
KLRS full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q2 2026
Previous quarter: Q4 2025
Kalaris Therapeutics, Inc. SEC filings
Kalaris Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 482929106
Recent filing periods:
Ownership snapshot
Top reported holders of KLRS - Kalaris Therapeutics, Inc. - Common Stock, $0.0001 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
RTW INVESTMENTS, LP
Disclosed value leader
Samsara BioCapital, LLC
Comparable rows
15/15
Latest evidence
31 Dec 2025
13D/G
13F
3/4/5
Lead comparable stake: 5.7%
13D/G row: RTW INVESTMENTS, LP
Showing 1-6 of 15 holder rows.
Quick read
RTW INVESTMENTS, LP leads the comparable SEC ownership view at 5.7%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens RTW INVESTMENTS, LP's linked filing trail.
Comparable ownership
Top 5
RTW INVESTMENTS, LP
5.7%
GILEAD SCIENCES, INC.
3.9%
Invus Global Management, LLC
1.5%
EcoR1 Capital, LLC
1.1%
Samsara BioCapital, LLC
54%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| RTW INVESTMENTS, LP |
13D/G
13F
Company
|
5.7%
|
$12,714,000
1,300,000 shares
|
$0 | 31 Dec 2025 |
| GILEAD SCIENCES, INC. |
3/4/5
13D/G
10%+ Owner
|
3.9%
from 13D/G
|
$11,158,950
16,635,286 shares
|
— | 27 Jun 2023 |
| Invus Global Management, LLC |
13D/G
Invus Public Equities, L.P.
|
1.5%
|
$754,533
282,586 shares
|
$0 | 30 Jun 2025 |
| EcoR1 Capital, LLC |
13D/G
|
1.1%
|
$1,315,201
201,718 shares
|
$0 | 31 Mar 2025 |
| Samsara BioCapital, LLC |
13F
Company
|
54%
|
$109,281,804
12,948,081 shares
|
— | 31 Dec 2025 |
| Paradigm Biocapital Advisors LP |
13F
Company
|
2.9%
|
$5,908,000
700,000 shares
|
— | 31 Dec 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
57
Shares
18,578,668
Rows available
57
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2026 vs Q4 2025 Across Filers
Q4 2025 holders
51
Q1 2026 holders
57
Holder diff
6
| Investor | Q4 2025 Shares | Q1 2026 Shares | Share Diff | Share Chg % | Q4 2025 value | Q1 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend